🔬 Bioscience Association Manitoba Applauds Government Action to Advance Bioscience Research and Clinical Trials in Manitoba

🤖 ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

👩‍⚕️ Synedgen Promotes Dr. Laura Saward to Chief Executive Officer and Appoints Dr. Kenton Gregory to Chief Medical Officer

🧬 Anne Wojcicki’s nonprofit gets court approval to buy 23andMe for $305 million

💡 Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer

🏥 Shriners Children’s to open $153M medical research facility in Atlanta

🚨 Biotech & Pharma Industry Highlights – Latest Announcements 🚨 Here are some recent developments shaping innovation across neuroscience, oncology, mental health, and regenerative medicine:

🔬 New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA Biogen presents new clinical data showing improved motor outcomes with a higher dose of nusinersen in SMA patients.

💊 PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares C$600,000 raised to support further development of psilocybin-based mental health therapies.

🧬 FDA Grants RMAT Designation for enGene’s Detalimogene A significant milestone for enGene’s bladder cancer gene therapy candidate, enabling faster review and development.

🧠 Biogen to Advance Investigational SMA Asset to Registrational Studies Positive Phase 1 results prompt progression of once-yearly ASO therapy for SMA to late-stage trials.

🧪 Enveric Biosciences Announces Data on EB-003 Lead compound targets serotonin receptors with the potential to treat depression and neurological conditions without hallucinogenic effects.

🌱 Triple Hair Group Signs Licensing Agreement for Brazil with Aché Strategic expansion into Brazil's $6B hair care market with exclusive rights granted to Aché.

📈 Quantum BioPharma Announces Private Placement $600M private placement to fund innovative treatments for neurodegenerative disorders through Lucid Psycheceuticals Inc.

🧫 Kane Biotech Converts Insider Loan and Reports AGM Results Governance updates and financial restructuring to support ongoing work in wound care and biofilm disruption.

💡 Follow the BioTech Weekly newsletter for more updates on biotech breakthroughs, regulatory milestones, and investment trends in life sciences.

#Biotech #Pharma #LifeSciences #ClinicalTrials #DrugDevelopment #HealthcareInnovation #SMA #CancerResearch #MentalHealth

Disclaimer: This podcast includes content generated with the help of large language models (LLM). Although care has been taken to ensure accuracy, LLMs can sometimes produce incorrect or misleading information. Listeners are advised to independently verify any details, provide feedback, and reach out.

🚨 BioTech Breakthroughs You Can't Miss – This Week in 7:30min Minutes 🎧

This week’s roundup features 14 key articles across 5 major categories (Strategic & Leadership Updates, Financing & Transactions, Clinical & Regulatory Developments, Policy & Market Shifts, Industry Vision & Commentary). From FDA policy moves and major layoffs to new funding rounds and pediatric trials, this summary highlights the momentum and challenges shaping biotech today.

🔬 Whether you're an investor, scientist, or biotech enthusiast, this episode is your shortcut to staying informed.

#biotech #pharmaceuticals #healthcareinnovation #podcast #drugdevelopment #clinicaltrials #biotechnews #lifesciences #investors #healthtech

Sources

🔍 Strategic Moves & Leadership Updates

• 👉 BMS banks on Wall Street vet for long-term strategy guidance— Chutes & Ladders
• 👉 FDA's CBER head dons extra hats with new CMO, CSO titles
• 👉 Isomorphic Labs taps CMO, plants roots in Boston

💰 Financing & Transactions

• 👉 PharmAla Files Preliminary Base Shelf Prospectus
• 👉 Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib
• 👉 PSYENCE GROUP INC. Announces Offering of up to C$600,000

🧪 Clinical & Regulatory News

• 👉 LabPMM® Receives New York State Approval for the NPM1 MRD Assay
• 👉 enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 👉 Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone

⚖️ Policy & Market Shifts

• 👉 FDA blocks new clinical trials that ship cells from US to China
• 👉 Industry reacts as FDA reportedly puts cell and gene therapy chief on leave
• 👉 Prothena lays off 63% of employees after phase 3 trial fail
• 👉 Syncona shifts biotech investment strategy amid tough market

🌍 Long-Term Vision

• 👉 The World Can’t Wait: Biopharma’s “Gold

🚀 Biotech & Life Sciences Weekly Highlights 🌱

1. Privacy Under Fire: 27 states and D.C. are suing 23andMe to stop the sale of personal genetic data without consent — as Regeneron eyes acquisition during bankruptcy proceedings.
2. Organoid Innovation: Pluristyx launches the PluriForm™ Organoid Kit, dramatically cutting down organoid development timelines with ready-to-differentiate iPSCs.
3. Funding Milestone: Genesys Capital closes its largest fund yet — Genesys Ventures IV LP — backing Canadian life sciences with strong investor confidence.
4. Rare Disease Breakthroughs: Chiesi Group partners with Key2Brain AB to advance blood-brain barrier-crossing therapies for lysosomal storage disorders.
5. Next-Gen Neurotherapeutics: Enveric Biosciences secures a patent for low-hallucinogenic neuroplastogens, opening new doors in psychiatric treatment.

🔍 Stay tuned — innovation is not slowing down!

Sources

• Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent
• Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines
• Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
• Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB
• Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens
• Five BIO 2025 events you don’t want to miss
• Layoff Tracker: Gilead Cuts 36 Employees in California

🚀 This week’s podcast covers a wide range of Biotech updates 🧬

Topics include a new gene-editing therapy used in a rare pediatric case, progress in cell sorting technologies, and recent patent activity in therapeutic development. If you’re looking for a brief, clear summary of what’s happening in the space, this episode offers a helpful overview.

🎧 Listen here.

#Biotech #LifeSciences #GeneTherapy #CRISPR #Healthcare #IndustryUpdate #Podcast #AI #NotebookLM

Sources:

• Baby saved by gene-editing therapy 'graduates' from hospital, goes home
• STEMCELL Technologies Announces Acquisition of Cellular Highways
• Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
• Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
• Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

Disclaimer: This podcast includes content generated with the help of large language models (LLM). Although care has been taken to ensure accuracy, LLMs can sometimes produce incorrect or misleading information. Listeners are advised to independently verify any details, provide feedback, and reach out.